TY - JOUR T1 - Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease JF - Evidence Based Medicine JO - Evid Based Med SP - 79 LP - 79 DO - 10.1136/ebm.10.3.79 VL - 10 IS - 3 A2 - , Y1 - 2005/06/01 UR - http://ebm.bmj.com/content/10/3/79.abstract N2 - Neri Serneri GG, Coccheri S, Marubini E, et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004;25:1845–52.OpenUrlAbstract/FREE Full Text 
 
 Q In patients with type 2 diabetes mellitus and peripheral arterial disease (PAD), is picotamide better than aspirin for preventing all cause mortality and major cardiovascular (CV) events? Clinical impact ratings IM/Ambulatory care ★★★★★★☆ Haematology ★★★★★★☆ Endrocrine ★★★★★★☆ Design: randomised placebo controlled trial (Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics [DAVID] study). Allocation: concealed.* Blinding: blinded (clinicians, patients, data collectors, outcome assessors, and data safety and monitoring committee).* Follow up period: 24 months. Setting: 86 centres in Italy. Patients: 1209 patients who were 40–75 years of age (mean age 64 y, 73% men) with type 2 diabetes for ⩾5 years and PAD (⩾2 of intermittent claudication for >2 mo, loss of posterior tibial pulse in the foot, ankle/arm pressure ratio <0.90 or >1.30 in the posterior or anterior tibial artery of the foot, amputation or reconstructive surgery in patients … ER -